Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imaging
- 1 February 2008
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 22 (2) , 123-131
Abstract
Objective The aim of this study was to evaluate the efficacy of dual-phase 99mTc-methoxyisobutylnitrile (MIBI) parathyroid scintigraphy (PS) and ultrasound (US) in primary (pHPT) and secondary (sHPT) hyperparathyroidism. Methods A total of 69 patients (mean age 47 ± 16; age range 14–79 years), including 19 patients with sHPT were enrolled in this study. Preoperative serum intact parathyroid hormone (iPTH) levels, calcium (Ca), phosphate (P), alkaline phosphatase, and 24-h urinary-free Ca measurements were obtained. Concomitant thyroid pathology was also recorded. Results Histopathology revealed 30 solitary adenomas and 71 hyperplastic glands in 55 patients. The remaining patients’ histopathology revealed normal parathyroid, thyroid, or lymph nodes. The sensitivities of MIBI and US in pHPT were 70% and 60%, respectively. It was 60% for both procedures in sHPT. The overall sensitivity of combined US + MIBI in pHPT and sHPT was 81% and 71%, respectively. The overall specificity of MIBI and US was 87% and 91%; positive predictive value (PPV) was 94% and 92%, respectively. MIBI and US identified the parathyroid pathology in 92% and 85% of patients in the non-concomitant thyroid disease group, and in 53% and 47% of patients in the concomitant thyroid disease group, respectively. The weight of the gland between primary and secondary hyperparathyroidism did not reveal a significant difference (P = 0.4). Significant differences were found with respect to age, PTH, Ca, and P levels between the pHPT and sHPT (P < 0.001). Intact PTH levels showed significant differences between MIBI positive and negative patients (P = 0.013), and also US positive and negative patients (P = 0.012). A significant negative correlation was found between iPTH and Ca at sHPT (P < 0.001). Conclusions The concomitancy of thyroid disease greatly influences scintigraphic and ultrasonographic detection of parathyroid pathology in pHPT and sHPT. The combination of MIBI and US appears promising for localizing parathyroid pathology in patients with both primary and secondary hyperparathyroidism. The concordance rate is high together with a lower chance of missing concomitant thyroid pathology, which might alter the surgical approach.Keywords
This publication has 43 references indexed in Scilit:
- Technetium-99m tetrofosmin for parathyroid scintigraphy: a direct comparison with 99mTc-MIBI, 201Tl, MRI and USEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Hyperparathyroid and Hypoparathyroid DisordersNew England Journal of Medicine, 2000
- Preoperative localization of parathyroid adenomas using 99mTc-MIBI scintigraphyThe American Journal of Medicine, 2000
- Pre-surgical localization of ectopic parathyroid glands using three-dimensional CT imaging, 99Tcm sestamibi, and 99Tcm tetrofosmin imaging.British Journal of Radiology, 1999
- LOCALIZATION OF ABNORMAL PARATHYROID GLANDS WITH JUGULAR SAMPLING FOR PARATHYROID HORMONE, AND SUBTRACTION SCANNING WITH SESTAMIBI OR TETROFOSMINEAnz Journal of Surgery, 1998
- Comparison of double-phase 99mTc-sestamibi with 123I-99mTc-sestamibi subtraction SPECT in hyperparathyroidism.American Journal of Roentgenology, 1997
- The complementary roles of fast spin-echo MR imaging and double-phase 99m Tc-sestamibi scintigraphy for localization of hyperfunctioning parathyroid glands.American Journal of Roentgenology, 1996
- Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoproteinSurgery, 1996
- Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retentionEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- 99Tcm sestamibi — a new agent for parathyroid imagingNuclear Medicine Communications, 1989